Key figures

Third quarter, 1 July – 30 September Q3 2024 Group
(figures in parentheses refer to the corresponding period in the previous year)

• Net sales amounted to 0.
• Other operating income amounted to SEK 3,730 (28) thousand.
• The profit after tax amounted to SEK -8,795 (-9,755) thousand.
• Earnings per share before and after dilution: -0.01 (-0.03) SEK. 
• Cash flow from current operations was SEK -12,611 (-9,313) thousand.

Nine months, 1 January – 30 September Q3 2024 Group

• Net sales amounted to 0 (0).
• Other operating income amounted to SEK 3,816 thousand (168).
• The profit after tax amounted to SEK -28,948 (-25,368) thousand.
• Earnings per share: -0.05 (-0.09) SEK. 
• Cash flow from current operations was SEK -21,499 (-23,286) thousand.

Significant events during the quarter

• The Psyros system was showcased at DxPx1 during the major
  international congress ADLM2 in Chicago from July 28 to August 1, 2024.
• In September, Prolight conducted a business review with its contract manufacturer
  for cartridges, FlexMedical Solutions (FMS). The review included an inspection of
  the pilot line for cardridge manufacturing and associated support facilities.
• The Psyros system was presented at the 2024 Cardiac Markers Dialogue
  Meeting, September 26–27 in Glasgow, UK.

Significant events after the end of the period

• In October, warrants of series TO7 were exercised for new shares in Prolight.
  The exercise period ran from October 7 to October 18 and were exercised to
  approximately 96.4 percent. Prolight raised approximately SEK 12.6 million before
  issue costs.
• Prolight was granted a European patent for the separation of plasma from whole blood
  within a fluidic consumable. The patent opens new potential business opportunities by
  incorporating the technology into other disposable fluidic systems.